TOBI · DIN 02239630 · 300 mg/5 mL · Inh Sol-5mL Pk
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
TOBI · DIN 02239630
Manufacturer: BGP Pharma ULC; listing date 2006-10-23
Health Canada: Marketed since 2021-10-06 · brand TOBI · ATC J01GB01 TOBRAMYCIN · form Solution · route Inhalation · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 300 MG/5ML · company Bgp pharma ulc · schedule Prescription
Ministry pays: $41.0985 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239630)
Source record
DIN 02239630: TOBI
Raw flags: sec3=Y
Item: 081228094; group id 51; item number 0108; lccId None; manufacturer id BGP
Source form: Inh Sol-5mL Pk; strength: 300mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $64.5832; ministry $41.0985
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239630
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63101
Therapeutic Notes (formulary)
For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.
Interchangeable products
Teva-Tobramycin · DIN 02389622 · $41.0985
Shortage status: not checked (no credentials)